Speciality Medicines BSE SME IPO GMP Today: +0% | Analysis & Score
Speciality Medicines BSE SME IPO GMP is +0% as of 20 March 2026. Read our analysis covering grey market premium, subscription status, composite score (2.5/10), and whether you should apply.
Speciality Medicines BSE SME IPO Overview
| Detail | Value |
|---|---|
| Issue Price | ₹124 |
| GMP | N/A |
| GMP % | +0% |
| Estimated Listing | TBA |
| Subscription | 0.3x |
| Lot Size | 1000 shares |
| IPO Size | ₹27.28 Cr |
| Category | SME |
| Open Date | 20-Mar |
| Close Date | 24-Mar |
| Listing Date | 30-Mar |
| Sentiment | Neutral |
Staqq Score: 2.5/10 (Avoid)
Our composite score evaluates this IPO across four key dimensions:
- GMP Signal: 4.0/10 (35% weight)
- Subscription Strength: 0.9/10 (30% weight)
- Company Quality: 2.0/10 (20% weight)
- Issue Size Signal: 3.0/10 (15% weight)
Confidence: high
GMP Analysis
GMP data is not yet available for this IPO. This usually means the grey market has not started trading the shares, which is common for IPOs that are still a few days away from opening.
Subscription Status
The IPO has a subscription of 0.3x, meaning it has not been fully subscribed yet. This could indicate tepid investor interest, and investors should watch for improvement in subscription numbers before the close date.
Should You Apply?
The numbers do not look encouraging for this IPO. Negative GMP sentiment and weak subscription interest suggest the market is not excited. Consider avoiding unless you see something the market is missing.
Last updated: 20 March 2026. GMP and subscription data change frequently. Check the Speciality Medicines BSE SME IPO page for the latest numbers.
Data sourced from grey market dealers and exchange filings. GMP is an unofficial indicator and should not be the sole basis for investment decisions.